The mammalian reoviruses have provided a valuable model for studying the pathogenesis of viral infections of the central nervous system (CNS). We have used this model to study the effect of antibody on disease produced by the neurally spreading reovirus type 3 (Dearing) (T3). Polyclonal and monoclonal antibodies protect mice from fatal infection with T3 after either footpad or intracerebral virus challenge. Protection occurs with monoclonal antibodies directed against the viral cell attachment protein sigma 1, and with polyclonal antisera without T3 sigma 1 binding activity. In vivo protection occurs with both neutralizing and nonneutralizing monoclonal antibodies. Antibody-mediated protection does not require serum complement and, under specific circumstances, can occur via Fc-independent mechanisms. Antibody can protect mice when transferred up to 5 days after intracerebral challenge and up to 7 days after footpad challenge, times when high titers of virus are present in the CNS. Thus, antibody mediated protection against this neurally spreading virus does not require neutralizing antibody or serum complement and occurs even in the face of established CNS infection.
The mammalian reoviruses have provided a valuable model for studying the pathogenesis of viral infections of the central nervous system (CNS). We have used this model to study the effect of antibody on disease produced by the neurally spreading reovirus type 3 (Dearing) (T3). Polyclonal and monoclonal antibodies protect mice from fatal infection with T3 after either footpad or intracerebral virus challenge. Protection occurs with monoclonal antibodies directed against the viral cell attachment protein sigma 1, and with polyclonal antisera without T3 sigma 1 binding activity. In vivo protection occurs with both neutralizing and nonneutralizing monoclonal antibodies. Antibody-mediated protection does not require serum complement and, under specific circumstances, can occur via Fc-independent mechanisms. Antibody can protect mice when transferred up to 5 days after intracerebral challenge and up to 7 days after footpad challenge, times when high titers of virus are present in the CNS. Thus, antibody mediated protection against this neurally spreading virus does not require neutralizing antibody or serum complement and occurs even in the face of established CNS infection.
Infection of neonatal mice with mammalian reoviruses has provided a useful model for studying viral pathogenesis. Some of the functions of the proteins encoded by individual viral genes at specific stages in reovirus pathogenesis have been identified (56, 61) . For example, following footpad (FP) inoculation with reovirus type 3 Dearing (hereafter designated T3), virus replicates in skeletal muscle and then spreads via nerves to the central nervous system (CNS) (63; K. L. Tyler and B. N. Fields, unpublished data). The capacity of T3 to spread via nerves is determined by the viral Si double-stranded RNA segment and occurs via the microtubule-associated pathway of fast axonal transport (63) . Section of the nerve innervating the site of inoculation protects mice against FP challenge with T3 (63) . This indicates that after inoculation via this route, neural spread of T3 is essential for lethal infection and that, in this setting, hematogenous spread does not contribute significantly to T3 pathogenesis. Once virus reaches the CNS, discrete populations of neural cells are infected, producing a lethal meningoencephalomyelitis (37, 62, 70) . The viral S1 gene plays a major role in determining the cell and tissue tropism of reoviruses in the CNS (60, 71, 73) , as well as the pattern of clearance of virus from the bloodstream in infected animals (64) .
Despite the increasing body of knowledge that has accumulated concerning viral pathogenesis in general and reovirus pathogenesis in particular, little is known about the specific mechanisms by which individual components of the host immune response (for example, immunoglobulin) influence the outcome of defined stages in viral pathogenesis. In addition, while antibody is protective against infection with a variety of viruses, the importance of antibody directed against specific viral determinants, the role of complement, and the role of the Fc portion of immunoglobulin are less clear. We chose to examine the effect of antibody on infection with T3 because the pathogenesis of infection with this virus following FP and intracerebral (IC) inoculation into neonatal mice is well understood. This system therefore provides an opportunity to define specific stages during infection with a neurotropic virus at which antibody can influence disease development.
In this article, we show that polyclonal and monoclonal antibodies (MAbs) protect neonatal mice against fatal infection with T3. This protection can be mediated by antibody directed against both the neutralization (NT) and hemagglutination-inhibition (HI) epitopes of the viral sigma 1 protein and by antibodies directed against virion proteins other than sigma 1. Protection can occur even after substantial amounts of virus are present in the CNS. Antibody-mediated protection does not require the presence of serum complement and, under certain circumstances, can occur without the participation of the Fc portion of immunoglobulin.
ANTIBODY PROTECTION AGAINST REOVIRUS T3
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(CVF) was injected either undiluted (25-,ul RIA. A two-layer solid-phase RIA was used to assess specificity of antibody preparations (65) . Purified virus in PBS with 0.02% (wt/vol) NaN3 (PBS-A) (50 ,ul at 50 jig/ml = ca. 5.7 x 101" particles per ml [57] ) was added to 96-well U-bottom flexible plates (MicroTest III, Falcon, Becton Dickinson Labware, Oxnard, Calif.). Plates were incubated at 4°C overnight, washed with PBS-A, and then incubated for several hours at room temperature with 100 ,ul of PBS-A per well, containing 10 mg of bovine serum albumin (Sigma Chemical Co., St. Louis, Mo.) (RIA-block) per ml. Fifty microliters of serial 0.5 log1o dilutions of antibody (starting at 30 jig/ml) or sera in RIA-block were then plated in duplicate on virus-coated or control wells. After incubation at 4°C overnight, plates were washed with PBS-A and the secondlayer antibody was added in RIA-block. For assay of mouse anti-reovirus MAbs, the second antibody was 1251I-rabbit anti-mouse immunoglobulin F(ab')2 fragment (Pel-Freez, Rogers, Ark.). For assay of rabbit anti-reovirus antibodies, 1251-mouse anti-rabbit immunoglobulin heavy and light chains (Accurate Chemical, Westbury, N.Y.) was used. After several hours at room temperature, plates were washed in PBS-A and individual wells were counted in a gamma counter. Reagents were iodinated by using chloramine T (23) . One hundred microliters of protein (1.0 mg/ml) was incubated with 2.0 mCi of sodium 1251 (Amersham Corp., Arlington Heights, Ill.) and 30 ,u1 of freshly prepared chloramine T (5 mg/ml) (Sigma Chemical Co., St. Louis, Mo.). After 15 min on ice, the reaction was stopped by adding 30 p.1 of freshly prepared Na2S205 (Sigma Chemical Co., St. Louis, Mo.). Unbound iodine was separated from labeled protein on a G-25 column (Pharmacia Diagnostics, Piscataway, N.J.), and the labeled reagent was stored in RIA-block at 4°C.
The amount of antibody present in serum at various times after passive transfer of T3 IgG or F(ab')2 T3 IgG was determined by RIA. Serum from neonatal mice injected with either T3 IgG or F(ab')2 T3 IgG was collected by adding 1 40 ,u1 of a 27.5-mg/ml solution of 2,2'-azinobis(3-ethylbenz-thiazoline sulfonic acid) per well. Plates were incubated (room temperature, 10 min), and the reaction was stopped by adding 100 p.1 of 0.2 M H3P04 per well. The optical density at 570 nm was then determined by using an ELISA reader.
Decomplementation of mice and assay of C3. Mice were decomplemented by using CVF (Naje haje [Egyptian] cobra, Diamedix Corporation, Miami, Fla.). CVF was suspended, frozen at -70°C, and used immediately after thawing. CVF was inactivated by heating (80°C, 1 h). Decomplementation was assessed by measuring C3 in plasma collected from neonatal mice by adding a single drop (20 to 50 pI) of blood to 200 pI of PBS containing 10 mM EDTA. After being spun in a Microfuge, plasma was frozen at -20°C prior to assay for C3. The amount of C3 was measured in a single-layer solid-phase RIA as previously described (66) . Goat antimouse C3 (Organon Teknika, West Chester, Pa.) was iodinated as described above. The amount of protein in each sample was equalized by using the optical density at 280 nm.
Samples were serially diluted in PBS (0.5 log1o steps), and 50 plI was added in duplicate to flexible 96-well plates. Plates were incubated (overnight at 4°C or 2 h at room temperature) and washed with PBS-A, and then 100 pI of RIA-block was added per well. After 1 h at room temperature, plates were washed in PBS-A and 50 plI of 1251-goat anti-mouse C3 was added per well. Plates were incubated at room temperature for 1 h and washed in PBS-A, and then individual wells were counted. All RIAs included normal adult and neonatal plasma as positive controls and CVF-treated adult and neonatal plasma as negative controls.
The specificity of the RIA for C3 was assessed using Western blot (immunoblot) analysis of proteins in normal and CVF-treated plasma. Samples of normal adult and neonatal plasma and of adult and neonatal plasma from mice treated 24 h before with 2.5 U of CVF were electrophoresed in 7.5% polyacrylamide gels under reducing conditions (20 mM iodoacetamide). Purified mouse C3, kindly provided by Winnie Wong (Department of Medicine, Brigham & Women's Hospital and Harvard Medical School), was used as a standard. Protein was transferred to nitrocellulose paper and then probed with '25I-goat anti-mouse C3 and autoradiographed.
RESULTS
Antibody protects mice from lethal infection with reovirus T3. We first identified a challenge dose of virus that was invariably lethal in untreated mice. The IC LD50 for T3 in 1-to 2-day-old CD-1 mice is 101 PFU per mouse (28, 58 ( Fig. 2 and 3 and Table 1 ). Anti-T3 serum, T3 IgG, and anti-Ti serum all have significant anti-T3 antibody activity (Fig. 2) and high plaque reduction NT titers (Table 1) . In contrast NRS, NRS IgG, and preimmune serum have no significant anti-T3 antibody activity (Fig. 2) or NT capacity (Table 1) . Anti-T3 serum showed significant binding to purified Ti, indicating that there are many shared epitopes between Ti and T3 (data not shown).
The extent of cross-reactivity between anti-Ti and anti-T3 serum was confirmed by immunoprecipitation which showed precipitation of most T3 proteins by anti-Ti serum (inset, Fig. 2 ). Anti-Ti serum did not precipitate the T3 sigma 1 protein even when undiluted serum was used (inset, Fig. 2 ). We confirmed this result by using a capture ELISA in which expressed T3 sigma 1 protein was bound to ELISA plates coated with G5 IgG (data not shown). The binding of NRS and anti-Ti serum was identical and did not vary between T3 sigma 1-coated and control plates. In contrast, anti-T3 serum showed significantly greater binding to T3 sigma 1-coated plates than to control plates. There was no significant binding of anti-Ti serum to the T3 sigma 1 protein under conditions which detected binding by anti-T3 serum at a 1/ 100,000 dilution. Thus, anti-Ti serum contains, at most, 0.001% of the anti-T3 sigma 1 activity of anti-T3 serum.
Since our rabbit anti-Ti serum does have T3 NT activity (Table 1) , the results of the immunoprecipitation and ELISA studies confirm that there are antibodies directed against proteins other than sigma 1 that are capable of neutralizing virus (26, 72) . We used third-bleed sera from rabbits immunized with large amounts of purified virus in complete Freund adjuvant. This may result in an increased amount of heterologous (non-type-specific) NT activity.
The antigenic specificity of G5 IgG for the T3 sigma 1 protein was assessed by RIA using purified T3, Ti, 1HA3, and 3HAi as antigens (Fig. 3) (Fig. 4) . Thirteen percent (9 of 68) of mice receiving normal saline and six percent (1 of 18) of mice receiving NRS survived T3 infection. Anti-T3 serum protected 100% of mice (10 of 10) from lethal FP challenge with T3 (Fig. 4) the capacity of protein A-purified T3 IgG to protect mice against T3 infection. Ninety-one percent (10 of 11) of mice receiving T3 IgG after IC viral challenge and seventy-eight percent (29 of 37) of mice receiving T3 IgG after FP challenge survived (Fig. 4) . In contrast, only 6% (1 of 17) mice challenged with T3 IC and 13% (1 of 8) of mice challenged with T3 in the FP survived after passive transfer of NRS IgG. Non-IgG components of anti-T3 serum were not protective (data not shown).
These results clearly indicate that polyclonal anti-T3 serum can protect mice against lethal challenge with T3 and that this protection is mediated by IgG.
Epitopes of T3 against which protective antibodies are directed. We next sought to identify the viral determinants against which our protective antibody was directed. The S1 gene, which encodes the outer capsid protein sigma 1 and the nonstructural protein sigma 1 ns, determines the CNS tropism and route of spread of reovirus in the infected host (60, 63, 71, 73) . We therefore began by testing the capacity of an affinity-purified NT MAb against the T3 sigma 1 protein (G5) to protect mice from challenge with T3. Ninety-four percent (46 of 49) of mice receiving G5 IgG were protected from either FP or IC challenge with T3 (Fig. 4) anti-Ti serum has significant amounts of cross-reacting antibody against many T3 virion proteins but no detectable antibody against the T3 sigma 1 protein (Results; Fig. 2 inset, column C). We therefore used this antiserum to test whether antibody binding T3 proteins other than sigma 1 could protect mice. One hundred percent of mice (9 of 9) challenged with T3 in the FP and ninety-four percent of mice (17 of 18) challenged IC survived after receiving anti-Ti serum (Fig. 4) . These results show that antibody directed against T3 viral proteins other than sigma 1 daily injections of either CVF (complement depleted) or heat-inactivated CVF (complement sufficient) starting on the day of birth. One-day-old mice were challenged via the FP with virus and passively transferred with antibody 24 h later. On day 7, the titers of the virus in brains were determined (Fig. 7) . We assessed protection by measuring brain titers of virus, rather than by survival, because of the difficulty in maintaining mice complement deficient for the time period required for protection studies. In the absence of antibody treatment, T3 titers in the brain exceeded 107 PFU. Decomplementation did not significantly alter the level of T3 infection. Antibody, in either the presence or absence of serum complement, reduced brain titers by approximately 100,000-fold. Thus, complement depletion did not affect the ability of G5 IgG to decrease virus titer in brain tissue after FP challenge with T3. F(ab')2 T3 IgG can inactivate T3 in vivo. To assess the role of the Fc portion of IgG in antibody-mediated protection against T3, we tested the protective capacity of F(ab')2 fragments of T3 IgG. While both T3 IgG and F(ab')2 T3 IgG are active in NT assays (Table 1) , a single dose (60 ,ug per mouse) of F(ab')2 did not protect mice from death after FP infection with T3 (9 of 9 mice died). An equal dose of T3 IgG protected 67% (6 of 9) of mice. However, when we measured the amount of antibody present in the serum of mice after IP injections of intact T3 IgG and F(ab')2 T3 IgG by RIA, we found that the half-life of F(ab')2 was less then 24 h, whereas that of intact T3 was >3 days (data not shown). Even when daily injections of F(ab')2 were given to neonatal mice, there was no protection against T3 infection and no effect on viral titers in CNS, and levels of F(ab')2 T3 IgG were significantly lower than antibody levels after a single dose of intact IgG (data not shown). Thus, the failure of F(ab')2 to protect mice may have resulted from inadequate antibody concentrations in the serum or CNS. One-day-old NIH(s) mice were inoculated in the hind limb FP with 100x LD50 of T3. At the indicated times after infection, mice received either G5 IgG or polyclonal anti-T3 serum and their subsequent percent survival was ascertained. In parallel experiments, the titers of T3 in the brains of untreated mice were determined at various times after infection. The bar graph shows the titer plus standard deviation of T3 in the brain at the indicated times after infection.
While the short half-life of F(ab')2 T3 IgG prevented assessment of the role of Fc under our usual experimental conditions, we still wished to assess the importance of an intact Fc in vivo. We therefore studied whether F(ab')2 T3 IgG bound to T3 in vitro was functional in vivo by mixing virus and antibody prior to infection. Equal volumes of T3 viral stock (5 x 107 to 5 x 108 PFU/ml) and either T3 IgG or F(ab')2 T3 IgG (600 ,ug/ml) were mixed in vitro. After incubation at 37°C for 60 min, mixtures were inoculated (0.1 ml) i.p. into neonatal mice. One hundred percent of mice receiving the T3-T3 IgG mixture survived (19 of 19) , while eighty percent of mice receiving the T3-F(ab')2 T3 IgG mixture survived (16 of 20) . In contrast, only 9% of mice receiving T3-saline lived. Thus, when F(ab')2 T3 IgG is allowed to combine with virus in vitro, it is capable of preventing lethal infection after i.p. inoculation.
Antibody protects against T3 infection even after substantial amounts of virus have reached the CNS. We examined the effect of progressively delaying antibody treatment after IC and FP viral challenge. Even 6 to 7 days following FP inoculation, G5 IgG protects 50% of mice (Fig. 8) . After IC challenge with T3, the 50% protection time point occurs after 5 days (Fig. 9) . Similar results were obtained when undiluted anti-T3 serum was used. To assess the extent of CNS infection at times when antibody can still act therapeutically, we measured the amount of virus at various times after FP or IC infection (Fig. 8 and 9 ). At the 50% protection point following FP inoculation, the viral titer in the brain was 7.8 log1o PFU per brain (day 7). The viral titer in the brain at the 50% protection point for IC inoculation was 7.1 log1o PFU per brain (day 5). These results show that antibody can protect 50% of animals even after massive CNS viral infection is established.
To confirm these results, we challenged mice with increasing doses of T3 IC and then treated them 24 h later with G5 IgG. Thirty-one mice were inoculated IC with between 4.9 log1o PFU and 6.9 log1o PFU of T3. At the highest dose tested (6.9 log1o PFU), 71% (5 of 7) of mice survived when given G5 IgG. This experiment shows that antibody protects (12, 30, 34, 35, 41, 42, 48) , and viruses that spread via the bloodstream (3, 38, 39, 45, 46) . Despite this, little is conclusively known about the stages in viral pathogenesis at which antibody acts or about the mechanisms by which this occurs. The mammalian reoviruses are useful to analyze these issues since a number of steps in reovirus pathogenesis have been mapped to specific viral genes, and the effect of antibodies can be studied. We feel that a better understanding of these issues is important to understanding viral pathogenesis and the immune response to viruses and for vaccine design and assessment.
Lack of a correlation between neutralization and protection. The mechanism of antibody-mediated protection in vivo may be related to measurable in vitro properties of antibody. An anti-reovirus MAb with NT activity protected against reovirus T3 (Fig. 4) . However, a non-NT MAb (Cl) and a MAb with only low NT capacity (F7) also protected mice from T3 (Fig. 5) . A similar lack of correlation between in vitro NT and protection has been observed among virtually all classes of viruses (4-6, 20, 25, 33, 39, 44, 51, 54, 59, 74) . Another property of antibodies against certain viruses is HI. The anti-reovirus G5 MAb protected mice but has no HI activity (7) , showing that HI is not required for protection against T3. A correlation between HI and protection has been suggested for measles (20, 50) but has not been seen with yellow fever virus (YFV) (9, 53 (Fig. 7) . The classical pathway of complement activation is not required for protection since F(ab')2 T3 IgG protected against T3. Complement plays a role in the host response to some viral infections (27, 42) , and a role for antibody-dependent, complement-mediated lysis of infected cells or alteration in viral clearance has been proposed as a mechanism of in vivo protection. Antibodydependent, complement-mediated lysis of cells expressing viral proteins could provide a mechanism for protection by MAbs against nonstructural virus proteins or by non-NT MAbs (4, 22, 39, 53, 54, 59 ). In agreement with our studies, complement-independent antibody-mediated protection has been described with Venezuelan encephalitis virus (39) , herpes simplex virus (1, 40, 47) , and rabies virus (42 (40, 47) , and Semliki Forest virus (4) . In several studies, the absence of a protective effect of F(ab')2 has been used as evidence for the importance of the Fc portion of IgG (4, 11, 36, 39 (44) and nonstructural proteins of YFV and Venezuelan encephalitis virus (22, 39, 53) , are also protective. Similarly, with Sindbis virus, non-NT antibodies to cryptic epitopes present on infected cell surfaces and present in, but not exposed on, intact virions are protective (54, 55) . Thus, expression of an epitope on the surface of a virus is not required for protection in vivo. It is possible that expression of T3 determinants on the surface of infected neural cells could serve as a target for protective antibody.
Amount of antibody required for protection. Approximately eight times more antibody was required to protect mice from IC than from FP infection with reovirus T3 (Fig.  6) . Similarly, more antibody is required to protect against IC compared with peripheral (e.g., oral, intramuscular) challenge with polio virus (2, 46 (5, 8) , poliovirus (34, 35) , and herpes simplex virus (41) but has not been universally observed (12, 14, 32, 41) . Antibody may act extracellularly at sites including the neuromuscular junction and synapses or at other sites within the CNS parenchyma. Alternatively, antibody may act intracellularly to inhibit critical steps in the viral life cycle (13, 17, 18, 21, 31) . Recent studies show that neurons pinocytose and transport antibody into the CNS (16, 75) , suggesting that intraneuronal antibody may be active in the CNS.
The studies described in this article show that antibody protects mice from the neurally spreading T3 reovirus. Antibody can act both early in the course of T3 infection and after substantial amounts of virus have entered the CNS ( Fig. 8 and 9 ). The fact that antibody protected against established CNS infection indicates that antibody inhibits steps in reovirus pathogenesis subsequent to viral entry into the CNS. Studies to be described elsewhere show that antibody acts at multiple steps in T3 pathogenesis, including blockade of viral entry into the CNS and prevention of spread within the CNS (Tyler et 
